Physician profile
Traci A Purath
NPI 1891716700
$524,066.80
in general payments reported to CMS, 2019-2025
14 companies · $141K in 2025
The $141K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $5,570 · 2021: $23K · 2022: $152K · 2023: $89K · 2024: $71K · 2025: $141K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Travel and Lodging: $27K · Honoraria: $23K · Consulting Fee: $14K · Food and Beverage: $6,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $231,057.50 |
| Travel and Lodging | $26,590.32 |
| Honoraria | $22,632.50 |
| Consulting Fee | $14,210.00 |
| Food and Beverage | $6,407.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240,393.34 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $93,317.16 | 2022 | |
| Pfizer INC. | $61,072.50 | 2023-2025 | |
| Amgen INC. | $49,024.20 | 2019-2022 | |
| Axsome Therapeutics, INC. | $22,787.27 | 2025 | Symbravo, Sunosi |
| Impel Pharmaceuticals INC. | $21,772.30 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $17,065.61 | 2020-2021 | |
| Lilly USA, LLC | $14,671.57 | 2022-2024 | Emgality |
| Tonix Medicines, INC. | $1,668.53 | 2024 | Zembrace Symtouch |
| Lundbeck LLC | $1,643.35 | 2024-2025 | Vyepti |
| Allergan, INC. | $400.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $165.66 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $53.17 | 2019 | |
| Novo Nordisk INC | $32.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Purath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.